| scholarly article | Q13442814 |
| P50 | author | Bart N M van Berckel | Q100745139 |
| Robert C Schuit | Q101132020 | ||
| Daniëlle M E van Assema | Q114430703 | ||
| Emile F I Comans | Q117267567 | ||
| Nikie J Hoetjes | Q117267568 | ||
| Philip Scheltens | Q22280357 | ||
| Oliver Langer | Q37830621 | ||
| Albert D. Windhorst | Q39190002 | ||
| Martin Bauer | Q48176743 | ||
| Adriaan A Lammertsma | Q52983347 | ||
| Wiesje van der Flier | Q57525101 | ||
| Mark Lubberink | Q91315268 | ||
| Nelleke Tolboom | Q100731554 | ||
| P2093 | author name string | Markus Müller | |
| P2860 | cites work | Role of the Blood-Brain Barrier in the Pathogenesis of Alzheimers Disease | Q22241329 |
| “Mini-mental state” | Q25938989 | ||
| Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease | Q27860795 | ||
| Neuropathological stageing of Alzheimer-related changes | Q27860862 | ||
| The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics | Q27860914 | ||
| Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption | Q28372143 | ||
| Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B | Q29012704 | ||
| Decreased clearance of CNS beta-amyloid in Alzheimer's disease | Q29616534 | ||
| Alzheimer's disease | Q29616743 | ||
| beta-Amyloid efflux mediated by p-glycoprotein | Q31962046 | ||
| Isolation of endothelial cells from brain, lung, and kidney: expression of the multidrug resistance P-glycoprotein isoforms | Q32125923 | ||
| Biochemical, cellular, and pharmacological aspects of the multidrug transporter | Q33636699 | ||
| Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease | Q33862071 | ||
| P-Glycoprotein, a gatekeeper in the blood-brain barrier | Q33904245 | ||
| Potential role of ABC transporters as a detoxification system at the blood-CSF barrier. | Q33981559 | ||
| Blood-brain barrier active efflux transporters: ATP-binding cassette gene family | Q33985133 | ||
| The blood-brain barrier and oncology: new insights into function and modulation | Q34119346 | ||
| Consensus nomenclature for in vivo imaging of reversibly binding radioligands | Q34630958 | ||
| Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease | Q34960461 | ||
| Importance of P-glycoprotein at blood-tissue barriers | Q35847121 | ||
| Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders | Q35883770 | ||
| Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. | Q36772901 | ||
| Age dependency of cerebral P-gp function measured with (R)-[11C]verapamil and PET. | Q36947632 | ||
| A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET | Q36949068 | ||
| Frequent amyloid deposition without significant cognitive impairment among the elderly | Q37085957 | ||
| Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. | Q37118134 | ||
| Beta-amyloid, blood vessels, and brain function | Q37246552 | ||
| Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans | Q37369295 | ||
| Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease | Q37378270 | ||
| The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. | Q37390988 | ||
| Transport of selected PET radiotracers by human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2): an in vitro screening. | Q39592140 | ||
| (R)- and (S)-[11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation. | Q40633547 | ||
| MR-based automatic delineation of volumes of interest in human brain PET images using probability maps | Q41798898 | ||
| P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model | Q41844698 | ||
| abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice | Q44371297 | ||
| Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [11C]verapamil measured with PET. | Q44671680 | ||
| Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat. | Q45251190 | ||
| Development of a tracer kinetic plasma input model for (R)-[11C]PK11195 brain studies | Q45296357 | ||
| Molecular imaging in the diagnosis of Alzheimer's disease: visual assessment of [11C]PIB and [18F]FDDNP PET images | Q45347226 | ||
| Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. | Q46151009 | ||
| Simplified parametric methods for [11C]PIB studies | Q46549565 | ||
| Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography | Q46551897 | ||
| Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration | Q46688887 | ||
| Blood-brain barrier P-glycoprotein function is not impaired in early Parkinson's disease. | Q46714452 | ||
| In vivo evaluation of P-glycoprotein function at the blood-brain barrier in nonhuman primates using [11C]verapamil | Q46809229 | ||
| Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease | Q46956885 | ||
| Classification analysis of P-glycoprotein substrate specificity | Q47326688 | ||
| MDR1-P-Glycoprotein (ABCB1) Mediates Transport of Alzheimer's amyloid-beta peptides--implications for the mechanisms of Abeta clearance at the blood-brain barrier | Q48116760 | ||
| MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging | Q48225787 | ||
| Tracer kinetic modeling of the 5-HT1A receptor ligand [carbonyl-11C]WAY-100635 for PET. | Q48352781 | ||
| Spectral analysis of dynamic PET studies | Q48366094 | ||
| RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease | Q48463448 | ||
| Two-year follow-up of amyloid deposition in patients with Alzheimer's disease | Q48467767 | ||
| Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans | Q48476417 | ||
| Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography | Q48502840 | ||
| Evaluation of tracer kinetic models for quantification of P-glycoprotein function using (R)-[11C]verapamil and PET. | Q48507860 | ||
| Simplified reference tissue model for PET receptor studies. | Q48832665 | ||
| Identification of pure subcortical vascular dementia using 11C-Pittsburgh compound B. | Q50801910 | ||
| Clearance of amyloid beta-peptide from brain: transport or metabolism? | Q52166981 | ||
| Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. | Q53388052 | ||
| Fully automated high yield synthesis of (R)- and (S)-[11C]verapamil for measuring P-glycoprotein function with positron emission tomography | Q54152616 | ||
| P433 | issue | Pt 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | blood–brain barrier | Q221694 |
| P304 | page(s) | 181-189 | |
| P577 | publication date | 2011-11-26 | |
| P1433 | published in | Brain | Q897386 |
| P1476 | title | Blood-brain barrier P-glycoprotein function in Alzheimer's disease. | |
| P478 | volume | 135 |
| Q37177013 | (R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP. |
| Q56346381 | A Proteomic Approach to Uncover Neuroprotective Mechanisms of Oleocanthal against Oxidative Stress |
| Q90333007 | A comprehensive review of Alzheimer's association with related proteins: Pathological role and therapeutic significance |
| Q47368185 | ABC Transporters Are Key Players in Alzheimer's Disease |
| Q35132580 | ABC transporter-driven pharmacoresistance in Amyotrophic Lateral Sclerosis |
| Q36404535 | Activity of P-Glycoprotein, a β-Amyloid Transporter at the Blood-Brain Barrier, Is Compromised in Patients with Mild Alzheimer Disease. |
| Q36638627 | Advances in PET imaging of P-glycoprotein function at the blood-brain barrier |
| Q57792155 | Age dependency of cerebral P-glycoprotein function in wild-type and APPPS1 mice measured with PET |
| Q26860478 | Age-related changes in brain support cells: Implications for stroke severity |
| Q91646694 | Alteration in the Function and Expression of SLC and ABC Transporters in the Neurovascular Unit in Alzheimer's Disease and the Clinical Significance |
| Q34353553 | Alzheimer's and ABC transporters--new opportunities for diagnostics and treatment. |
| Q38087640 | Alzheimer's disease drug development: translational neuroscience strategies |
| Q46165463 | Alzheimer's disease: A matter of blood-brain barrier dysfunction? |
| Q52644592 | Amsterdam Dementia Cohort: Performing Research to Optimize Care. |
| Q37243920 | Amyloid beta accumulation in HIV-1-infected brain: The role of the blood brain barrier |
| Q30352343 | An application of Pavlovian principles to the problems of obesity and cognitive decline |
| Q93049131 | Approaches to CNS Drug Delivery with a Focus on Transporter-Mediated Transcytosis |
| Q36564557 | Aβ40 Reduces P-Glycoprotein at the Blood-Brain Barrier through the Ubiquitin-Proteasome Pathway. |
| Q35996706 | Behavioral effects and central nervous system levels of the broadly available κ-agonist hallucinogen salvinorin A are affected by P-glycoprotein modulation in vivo |
| Q38646588 | Blood-Brain Barrier Driven Pharmacoresistance in Amyotrophic Lateral Sclerosis and Challenges for Effective Drug Therapies. |
| Q41660607 | Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer's Disease |
| Q57023036 | Blood-Brain Barrier: From Physiology to Disease and Back |
| Q36353785 | Blood-brain barrier P-glycoprotein function in healthy subjects and Alzheimer's disease patients: effect of polymorphisms in the ABCB1 gene |
| Q47707801 | Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders |
| Q37216153 | Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease. |
| Q98384539 | Blood-brain barrier integrity in the pathogenesis of Alzheimer's disease |
| Q39088427 | CJY, an isoflavone, interacts with ATPase of P-glycoprotein in the rat brain microvessel endothelial cells (RBMECs). |
| Q88295850 | Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy |
| Q47738183 | Disease-Induced Alterations in Brain Drug Transporters in Animal Models of Alzheimer's Disease : Theme: Drug Discovery, Development and Delivery in Alzheimer's Disease Guest Editor: Davide Brambilla. |
| Q38260539 | Drug access to the central nervous system in Alzheimer's disease: preclinical and clinical insights. |
| Q36587065 | Early brain injury alters the blood-brain barrier phenotype in parallel with β-amyloid and cognitive changes in adulthood |
| Q39290800 | Efflux proteins at the blood-brain barrier: review and bioinformatics analysis |
| Q57810063 | Elimination of substances from the brain parenchyma: efflux via perivascular pathways and via the blood-brain barrier |
| Q39647414 | Evaluation of [18F]MC225 as a PET radiotracer for measuring P-glycoprotein function at the blood-brain barrier in rats: Kinetics, metabolism, and selectivity |
| Q38705664 | From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery |
| Q50894478 | From the Cover: Comparative Proteomics Reveals Silver Nanoparticles Alter Fatty Acid Metabolism and Amyloid Beta Clearance for Neuronal Apoptosis in a Triple Cell Coculture Model of the Blood-Brain Barrier. |
| Q46977559 | Glucocorticoids modify effects of TGF-β1 on multidrug resistance in the fetal blood-brain barrier. |
| Q26781578 | Herpes Simplex Virus Type 1 and Other Pathogens are Key Causative Factors in Sporadic Alzheimer's Disease |
| Q26995364 | How do immune cells support and shape the brain in health, disease, and aging? |
| Q38198632 | Imaging of cerebrovascular pathology in animal models of Alzheimer's disease |
| Q38871905 | Imaging transporters: Transforming diagnostic and therapeutic development |
| Q39795136 | Impact of Ageing on Serum Concentrations of Risperidone and Its Active Metabolite in Patients with Known CYP2D6 Genotype |
| Q37351380 | Impaired mitochondrial energy production and ABC transporter function-A crucial interconnection in dementing proteopathies of the brain |
| Q30524688 | Inflammation-induced dysfunction of the low-density lipoprotein receptor-related protein-1 at the blood-brain barrier: protection by the antioxidant N-acetylcysteine |
| Q35095391 | Influence of ATP-binding cassette polymorphisms on neurological outcome after traumatic brain injury |
| Q35529180 | Influence of P-Glycoprotein Inhibition or Deficiency at the Blood-Brain Barrier on (18)F-2-Fluoro-2-Deoxy-D-glucose ( (18)F-FDG) Brain Kinetics |
| Q90654130 | Intestinal Permeability and Oral Absorption of Selected Drugs Are Reduced in a Mouse Model of Familial Alzheimer's Disease |
| Q38365567 | Is Vasomotion in Cerebral Arteries Impaired in Alzheimer's Disease? |
| Q57112716 | Isolation of Cerebral Capillaries from Fresh Human Brain Tissue |
| Q89879977 | Lipids and Alzheimer's Disease |
| Q22001058 | Mild chronic cerebral hypoperfusion induces neurovascular dysfunction, triggering peripheral beta-amyloid brain entry and aggregation |
| Q60046676 | Molecular Bases of Alzheimer’s Disease and Neurodegeneration: The Role of Neuroglia |
| Q35768413 | Molecular Imaging of Membrane Transporters' Activity in Cancer: a Picture is Worth a Thousand Tubes |
| Q90220710 | Nanomaterial-based blood-brain-barrier (BBB) crossing strategies |
| Q60303358 | Nanoparticle-conjugated nutraceuticals exert prospectively palliative of amyloid aggregation |
| Q99730750 | Neuronal Activity Regulates Blood-Brain Barrier Efflux Transport through Endothelial Circadian Genes |
| Q36170367 | No evidence for additional blood-brain barrier P-glycoprotein dysfunction in Alzheimer's disease patients with microbleeds |
| Q28285617 | Olive-oil-derived oleocanthal enhances β-amyloid clearance as a potential neuroprotective mechanism against Alzheimer's disease: in vitro and in vivo studies |
| Q40597133 | P-Glycoprotein Altered Expression in Alzheimer's Disease: Regional Anatomic Variability |
| Q52662563 | P-Glycoprotein, not BCRP, Limits the Brain Uptake of [(18)F]Mefway in Rodent Brain. |
| Q47873232 | P-glycoprotein (ABCB1) and Oxidative Stress: Focus on Alzheimer's Disease |
| Q36382013 | P-glycoprotein function at the blood-brain barrier: effects of age and gender |
| Q38259301 | P-glycoprotein trafficking as a therapeutic target to optimize CNS drug delivery |
| Q48956010 | Permeability of blood-brain barrier in macaque model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson disease |
| Q58555658 | Pharmacoepigenomic Interventions as Novel Potential Treatments for Alzheimer's and Parkinson's Diseases |
| Q39275819 | Pharmacokinetic and pharmacodynamic alterations in older people with dementia |
| Q29048615 | Pharmacological targeting of the PDGF-CC signaling pathway for blood-brain barrier restoration in neurological disorders |
| Q92939071 | Preclinical Development of Crocus sativus-Based Botanical Lead IIIM-141 for Alzheimer's Disease: Chemical Standardization, Efficacy, Formulation Development, Pharmacokinetics, and Safety Pharmacology |
| Q38248506 | Pregnane X Receptor and P-glycoprotein: a connexion for Alzheimer's disease management |
| Q55716450 | Preventing P-gp Ubiquitination Lowers Aβ Brain Levels in an Alzheimer's Disease Mouse Model. |
| Q38166961 | Radioligands targeting P-glycoprotein and other drug efflux proteins at the blood-brain barrier. |
| Q38351240 | Radiopharmaceuticals for assessing ABC transporters at the blood-brain barrier. |
| Q36863138 | Rapid in vivo measurement of β-amyloid reveals biphasic clearance kinetics in an Alzheimer's mouse model |
| Q36378047 | Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders |
| Q35742284 | Reproducibility of quantitative (R)-[11C]verapamil studies |
| Q36418108 | Role of ABC transporters in the pathogenesis of Alzheimer's disease |
| Q92755051 | Streptococcus agalactiae disrupts P-glycoprotein function in brain endothelial cells |
| Q37665371 | Susceptibility to focal and global brain ischemia of Alzheimer mice displaying aβ deposits: effect of immunoglobulin |
| Q57191515 | Synthesis and preliminary preclinical evaluation of fluorine-18 labelled isatin-4-(4-methoxyphenyl)-3-thiosemicarbazone ([F]4FIMPTC) as a novel PET tracer of P-glycoprotein expression |
| Q38976934 | Synthesis, and the antioxidant, neuroprotective and P-glycoprotein induction activity of 4-arylquinoline-2-carboxylates. |
| Q97549241 | The 3D Brain Unit Network Model to Study Spatial Brain Drug Exposure under Healthy and Pathological Conditions |
| Q53397945 | The Biological Activities of Oleocanthal from a Molecular Perspective. |
| Q38157892 | The changing landscape of voltage-gated calcium channels in neurovascular disorders and in neurodegenerative diseases |
| Q27026331 | The development, past achievements, and future directions of brain PET |
| Q59784797 | The role of brain vasculature in neurodegenerative disorders |
| Q91860762 | The role of mutations associated with familial neurodegenerative disorders on blood-brain barrier function in an iPSC model |
| Q90420762 | Theoretical Prediction of the Complex P-Glycoprotein Substrate Efflux Based on the Novel Hierarchical Support Vector Regression Scheme |
| Q38905608 | Transporters as Drug Targets in Neurological Diseases |
| Q35027962 | Vascular and extravascular distribution of the ATP-binding cassette transporters ABCB1 and ABCC1 in aged human brain and pituitary. |
| Q38099191 | Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position. |
| Q42354388 | [11C]phenytoin revisited: synthesis by [11C]CO carbonylation and first evaluation as a P-gp tracer in rats |
| Q52710136 | [MUV researcher of the month, March 2015]. |
Search more.